About abrocitinib
Janus kinase 1 inhibitor
Used for
- Treats moderate-to-severe atopic dermatitis in adults and adolescents when other systemic treatments are unsuitable or inadequate.
Usual adult dose
Usually 100 mg once daily; may increase to 200 mg once daily if needed and appropriate.
Usual dose in children
For adolescents aged 12 years and older: usually 100 mg once daily; may increase to 200 mg once daily if needed and appropriate.
Common side effects
- Nausea
- Headache
- Acne
- Infections, including herpes simplex or shingles
Important warnings
- Can increase serious infection risk; tuberculosis screening is required before treatment.
- May cause blood clots, serious cardiovascular events, or cancer; risks are higher in some people.
- Blood counts and cholesterol may need monitoring.
- Avoid live vaccines during treatment.
Pregnancy
Not recommended during pregnancy; reliable contraception is advised during treatment and for one month after the final dose.
Breastfeeding
Avoid breastfeeding during treatment and for one day after the final dose.
Interactions
- Strong CYP2C19 or CYP2C9 inhibitors can increase abrocitinib exposure.
- Strong CYP2C19 or CYP2C9 inducers can reduce its effectiveness.
- Avoid combining with other JAK inhibitors, biologic immunomodulators, or potent immunosuppressants.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.